经直肠超声改善妇科间质施源器植入的应用
回顾性单中心研究纳入2020至2023年需间质近距离治疗的139例患者共142次植入,比较使用经直肠超声(TRUS)与未使用者的针道利用与剂量学。TRUS使用率73%,与每次植入减少4-5根针相关,模拟时拔针率从41%降至3%,空载通道计划从76%降至25%,直肠D2cc<75 Gy达标率92%对56%,靶区覆盖相当。
要点
- TRUS使用与每次植入减少4-5根针相关,且不依赖CTV_HR体积。
- 使用TRUS时模拟时拔针率从41%降至3%(p<0.001)。
- 使用TRUS时空载针通道计划从76%降至25%(p<0.001)。
核心结论
- TRUS改善间质针植入效率与直肠剂量学,不损害靶区覆盖,其可及性支持更广泛整合入妇科近距离治疗流程。
研究设计与样本
- 回顾性单中心研究,纳入2020至2023年需间质近距离治疗的患者,按是否使用TRUS分组,共142次植入、139例患者。
主要发现
- 58%的植入未使用 tandem,代表子宫切除后复发或原发性阴道癌。
- CTV_HR平均体积为59 cc。
- TRUS使用率73%,与每次植入减少4-5根针相关,独立于CTV_HR体积。
- 使用TRUS时模拟时拔针率从41%降至3%(p<0.001),空载针通道计划从76%降至25%(p<0.001)。
- 根治性宫颈癌中CTV_HR覆盖相当:TRUS组D90>85 Gy EQD2者79%,无TRUS组78%。
关键数值与推荐
- ABS直肠约束D2cc<75 Gy达标率:TRUS组92% vs 无TRUS组56%(p<0.001)。
- CTV_HR覆盖D90>85 Gy EQD2:TRUS组79% vs 无TRUS组78%。
临床怎么用
- TRUS可作为妇科间质近距离治疗中优化针植入与直肠剂量学的实用工具,以助疾病控制并减少毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Brachytherapy is essential for treating locally advanced cervical cancer and vaginal recurrences post-hysterectomy. While MRI and CT have permitted volumetric planning, precise interstitial applicator placement remains crucial for optimal dosimetry. We evaluated the impact of transrectal ultrasound (TRUS) on interstitial gynecologic brachytherapy needle utilization and dosimetry. METHODS: A retrospective single institute study was conducted of patients requiring interstitial brachytherapy between 2020 and 2023. Cases were categorized based on TRUS use. Endpoints included number of needles placed, removed, unloaded channels, and dosimetry to the high risk clinical target volume (CTV_HR) and organs at risk. RESULTS: A total of 142 implants were performed on 139 patients; 58 % did not utilize a tandem, representing post-hysterectomy recurrences or primary vaginal cancers. Mean CTV_HR volume was 59 cc. TRUS was used in 73 % of cases and was associated with 4-5 fewer needles per implant, independent of CTV_HR volume. With TRUS, needle removal at simulation decreased from 41 % to 3 % (p < 0.001), and plans with unloaded needle channels decreased from 76 % to 25 % (p < 0.001). Despite fewer needles, CTV_HR coverage among definitive cervical cancers remained comparable (D90 > 85 Gy EQD2 in 79 % with TRUS and 78 % without). The ABS rectal constraint of D2cc < 75 Gy was met more often with TRUS (92 % vs. 56 %, p < 0.001). CONCLUSIONS: TRUS improves interstitial needle placement efficiency and rectal dosimetry without compromising target coverage. Its accessibility supports broader integration into gynecologic brachytherapy workflows as a practical optimization tool for achieving disease control and minimizing toxicity.
引用
- Ragland K, Pogue J, Simiele E, et al. The use of transrectal ultrasound to improve gynecologic interstitial applicator implantation. Gynecol Oncol. 2025. PMID: 40700854. doi:10.1016/j.ygyno.2025.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。